Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.

Li R, Cheng C, Chong SZ, Lim AR, Goh YF, Locht C, Kemeny DM, Angeli V, Wong WS, Alonso S.

Allergy. 2012 Oct;67(10):1250-8. doi: 10.1111/j.1398-9995.2012.02884.x. Epub 2012 Aug 22.

2.

Mucosal immunity and nasal influenza vaccination.

Rose MA, Zielen S, Baumann U.

Expert Rev Vaccines. 2012 May;11(5):595-607. doi: 10.1586/erv.12.31. Review.

PMID:
22827245
3.

Vaccines against mucosal infections.

Holmgren J, Svennerholm AM.

Curr Opin Immunol. 2012 Jun;24(3):343-53. doi: 10.1016/j.coi.2012.03.014. Epub 2012 May 12. Review.

4.

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T.

J Clin Immunol. 2012 Jun;32(3):595-603. doi: 10.1007/s10875-011-9632-5. Epub 2012 Feb 9.

PMID:
22318394
5.

The perpetual challenge of infectious diseases.

Fauci AS, Morens DM.

N Engl J Med. 2012 Feb 2;366(5):454-61. doi: 10.1056/NEJMra1108296. No abstract available. Erratum in: N Engl J Med. 2012 Mar 1;366(9):868.

6.

Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates.

Weinfurter JT, Brunner K, Capuano SV 3rd, Li C, Broman KW, Kawaoka Y, Friedrich TC.

PLoS Pathog. 2011 Nov;7(11):e1002381. doi: 10.1371/journal.ppat.1002381. Epub 2011 Nov 10.

7.

Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.

Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, Alonso S.

Vaccine. 2011 Jul 26;29(33):5502-11. doi: 10.1016/j.vaccine.2011.05.052. Epub 2011 May 30.

PMID:
21624415
8.

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC.

J Exp Med. 2011 Jan 17;208(1):181-93. doi: 10.1084/jem.20101352. Epub 2011 Jan 10. Erratum in: J Exp Med. 2011 Feb 14;208(2):411.

9.

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.

Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C.

Vaccine. 2010 Oct 8;28(43):7047-53. doi: 10.1016/j.vaccine.2010.08.017. Epub 2010 Aug 13.

PMID:
20708998
10.

Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.

Li R, Lim A, Phoon MC, Narasaraju T, Ng JK, Poh WP, Sim MK, Chow VT, Locht C, Alonso S.

J Virol. 2010 Jul;84(14):7105-13. doi: 10.1128/JVI.02542-09. Epub 2010 May 5.

11.

Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.

Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon BP.

Clin Exp Allergy. 2010 Jun;40(6):933-41. doi: 10.1111/j.1365-2222.2010.03459.x. Epub 2010 Feb 22.

PMID:
20184606
12.

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.

Mielcarek N, Debrie AS, Mahieux S, Locht C.

Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27.

13.

A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP.

Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22.

14.

A universal epitope-based influenza vaccine and its efficacy against H5N1.

Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T.

Vaccine. 2009 Mar 26;27(15):2099-107. doi: 10.1016/j.vaccine.2009.02.011. Epub 2009 Feb 13.

PMID:
19356612
15.

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Schotsaert M, De Filette M, Fiers W, Saelens X.

Expert Rev Vaccines. 2009 Apr;8(4):499-508. doi: 10.1586/erv.09.6. Review.

16.

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.

Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C.

Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30.

PMID:
18762220
17.

Influenza.

Beigel JH.

Crit Care Med. 2008 Sep;36(9):2660-6. doi: 10.1097/CCM.0b013e318180b039. Review.

18.

Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Ho SY, Chua SQ, Foo DG, Locht C, Chow VT, Poh CL, Alonso S.

Infect Immun. 2008 Jan;76(1):111-9. Epub 2007 Oct 22.

19.

Vaccines for preventing influenza in healthy adults.

Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001269. Review. Update in: Cochrane Database Syst Rev. 2010;(7):CD001269.

PMID:
17443504
20.

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.

Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C.

PLoS Pathog. 2006 Jul;2(7):e65.

Supplemental Content

Support Center